Cosmic Peptides research library

Research-use-only compliance

What "research use only" means in law, how the FDA decides what a product is really for, the mistakes that turn research chemicals into unapproved drugs, what strict compliance costs, and where regulation is heading. We publish this because we think it should be discussed openly.

Latest piece · Editorial policy

In the United States

  1. Part 1
    Are research peptides legal in the US? No federal law bans them, but selling them for use in people is a crime

    No federal law bans research peptides, and none is a controlled substance. Under the Federal Food, Drug, and Cosmetic Act a peptide is a drug when it is intended for use in people, judged from everything its seller says and does, and selling an unapproved drug is a federal crime. The drug schedules, the drug definition, FDA's warning letters, the penalties, the 2026 compounding changes, the state rules, and where laboratory research stands.

  2. Part 2
    What "research use only" means in law

    A research-use-only label is a statement of intent. Under federal drug law, intent is judged from everything a seller says and does, and a disclaimer cannot outweigh the rest of the evidence.

  3. Part 3
    How the FDA decides what a product is for

    What FDA's 2025–2026 warning letters to research-use-only peptide sellers quote as evidence of intended use, from direct claims and coded names to solvents, calculators and category text.

  4. Part 4
    Common mistakes in research-use-only supply

    Seventeen decisions, each commercially sensible on its own, that turn research chemicals into unapproved drugs in the eyes of the law.

  5. Part 5
    What strict compliance costs

    Strict research-use-only compliance removes most of the market, closes the fastest channels and adds permanent overhead. Why it is a business model, not a disclaimer.

  6. Part 6
    Where research-use-only regulation is heading

    What has already changed in how FDA finds and acts on violations, what we expect next, and the capabilities a research-use-only platform will need to prove its compliance.

  7. Part 7
    FDA's Category 2 peptide list now names one peptide for pharmacies, kisspeptin-10, after 17 withdrawals

    FDA added 19 substances to Category 2 of its 503A compounding policy on September 29, 2023, nearly all of them peptides. Five left in September 2024 and twelve on April 22, 2026, each because its nomination was withdrawn, and kisspeptin-10 is the only peptide still there for state-licensed pharmacies. Every peptide, its dates, FDA's stated concerns, the advisory committee votes, what Category 1, 2 and 3 mean, and why none of it governs research-labeled peptides.

  8. Part 8
    Research peptides vs compounded peptides: one is a lab chemical, the other a prescription drug from a pharmacy

    The same peptide can be a laboratory chemical or a compounded prescription drug, and US law regards the two as different things. What section 503A requires of a compounded peptide, what keeps a research peptide outside the drug laws, why research material cannot become a compounding ingredient, which compounded peptides are lawful, and where the October 2026 HHS notice and the state rules fit.

Around the world

  1. Part 1
    How research peptides are regulated around the world

    The same vial of BPC-157 is sold for research in the United States, the United Kingdom, the European Union, Canada and Australia, under five definitions of a medicine. The four questions every system answers, how each answers them, the enforcement record of 2025 and 2026 in each, and what is the same everywhere: the research label is evidence of intent, never an exemption.

  2. Part 2
    Research peptides in the United Kingdom: medicines by presentation or by function

    Under the Human Medicines Regulations 2012 a peptide is a medicine by presentation or by function, decided case by case by the MHRA. The two tests, how the agency applies them, why possession is not an offence, the melanotan precedent from 2008 to 2013, the 2025 and 2026 enforcement record, the April 2026 clinic investigation, the advertising regulator and the border, and where a research peptide sold with no claims actually stands.

  3. Part 3
    Research peptides in Australia: the substance is scheduled, so the label does not matter

    Australia regulates the molecule, not the claim. BPC-157 has been a Schedule 4 substance in Appendix D of the Poisons Standard since June 1, 2024, so possession without authority is an offence whatever the label says. The Act, the scheduling system, how a sporting scandal in 2013 shaped the rules, the enforcement record from a $10 million court penalty to the 2026 compliance priority, and what it means for research material.

  4. Part 4
    Research peptides in Canada: prescription drugs by definition, and no exemption for the label

    Canada's Food and Drugs Act defines a drug by what it is sold or represented for, and Health Canada regards most peptides sold in vials as prescription drugs that cannot be sold without a drug identification number. The statute and regulations, the department's published rejection of research labeling, four public advisories and three seizures between December 2023 and April 2026, the permanent injunction granted by the Superior Court of Québec in June 2026, the border rules, and where research material stands.

  5. Part 5
    Research peptides in the European Union: one definition, twenty-seven enforcers, and a Dutch record

    Directive 2001/83/EC defines a medicine by presentation or by function and resolves doubt in favour of medicines law; each member state enforces it. The three Court of Justice rulings that decide when a peptide is a medicine by function, the Netherlands' 2026 sequence of laboratory tests, order and €10,000-a-day penalty, Germany's medicines and doping statutes and which peptides the doping annex names, the Swiss and Icelandic seizures, the border inside and outside the single market, and where research material stands.

Records

  1. FDA enforcement tracker

    Every published FDA warning letter to an online seller of research-labeled peptides, 17 so far, with the products named, the disclaimer quoted and the evidence cited.

  2. Regulatory timeline

    The statutes, court decisions, regulations and FDA guidance that shape how research-use-only peptides are regulated, from 1906 to today, each with its citation.

Cite this page

Text

Cosmic Peptides. (2026, November 8). Research-use-only compliance. Cosmic Peptides Research Library. Retrieved November 15, 2026, from https://cosmicpeptides.com/research/compliance

BibTeX

@misc{cosmicpeptides_research_compliance,
  author       = {{Cosmic Peptides}},
  title        = {Research-use-only compliance},
  howpublished = {Cosmic Peptides Research Library},
  year         = {2026},
  month        = nov,
  url          = {https://cosmicpeptides.com/research/compliance},
  urldate      = {2026-11-15},
  note         = {Last reviewed 2026-11-08}
}

RIS

TY  - ELEC
AU  - Cosmic Peptides
TI  - Research-use-only compliance
T2  - Cosmic Peptides Research Library
PB  - Cosmic Peptides
PY  - 2026
DA  - 2026/11/08
UR  - https://cosmicpeptides.com/research/compliance
Y2  - 2026/11/15
LA  - en
ER  - 

Cite the date the page was last reviewed, November 8, 2026, as its version. Reference managers such as Zotero can save this page directly.

Changes to this page

  1. Updated Research peptides vs compounded peptides: one is a lab chemical, the other a prescription drug from a pharmacy

    Part 8 of the United States series: research peptides and compounded peptides side by side, what section 503A and section 503B require, what keeps a research peptide outside the drug laws, why research material cannot become a compounding ingredient, which compounded peptides are lawful, and the HHS notice and state rules.

  2. Updated FDA's Category 2 peptide list now names one peptide for pharmacies, kisspeptin-10, after 17 withdrawals

    Part 7 of the United States series: every peptide FDA placed in Category 2 of its 503A compounding policy, from FDA's category documents of 2021 to May 2026, when and why each left, the 2024 and 2026 advisory committee votes, the peptides still in Category 2 and Category 1, and what the categories mean.

  3. Updated Are research peptides legal in the US? No federal law bans them, but selling them for use in people is a crime

    Part 1 of the United States series: the direct answer to whether research peptides are legal, with the federal drug schedules, the drug definition and the intended-use regulation, FDA's warning letters and what they are worth, the penalties and the 2026 sentencing, the HHS compounding notice and the 503A list, the state rules, and where laboratory research stands.

  4. Updated Research peptides in the European Union

    Part 5 of the international series: the Directive's definition and doubt rule, the Court of Justice test for a medicine by function, the Netherlands' 2026 laboratory tests, order and penalty, Germany's medicines and doping statutes, the Swiss and Icelandic seizures, the single market and the EMA's synthetic-peptide guideline. The timeline gains Hecht-Pharma, the Dutch tests and order, and the Swiss action.

  5. Updated Research peptides in Canada

    Part 4 of the international series: the Food and Drugs Act's definition by representation, the DIN and prescription rules, Health Canada's published rejection of research labeling, the record from the December 2023 stop order through three seizures to the June 2026 injunction, and the border. The timeline gains the 2023 stop order and the 2024 and 2025 seizures.

  6. Updated Research peptides in the United Kingdom and in Australia

    The first two country pages of the international series. The United Kingdom: medicines by presentation or by function, the MHRA's method, the melanotan precedent, the 2025 and 2026 record and the April 2026 clinic investigation. Australia: the Act, the Poisons Standard and BPC-157's Schedule 4 and Appendix D entry, the Essendon case, the enforcement record from 2019 to the 2026 compliance priority. The timeline gains the melanotan warnings, the Essendon award, the BPC-157 scheduling and the TGA priority.

  7. Updated How research peptides are regulated around the world

    The first page of a series on research peptides outside the United States: the four questions every system answers, the United States, United Kingdom, European Union, Canada and Australia side by side, sport and the source, and what is the same everywhere. The timeline gains the MHRA investigation, Health Canada's seizures, advisory and injunction, and the TGA alerts; the glossary gains medicinal product by presentation, the Poisons Standard and import alert.

Changes of substance are listed here; wording changes are not. Every correction is also on the corrections log.

For in vitro laboratory research only. Not for human or veterinary use. This library describes chemistry, analytical methods and published laboratory research; it gives no guidance on use in people or animals.